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1. INTRODUCTION {#hed25583-sec-0005}
===============

Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer by incidence worldwide, causing more than 200 000 deaths per year.[1](#hed25583-bib-0001){ref-type="ref"} HNSCC occurs in various sites within the head and neck region, including oral cavity, oropharynx, hypopharynx, and larynx.[2](#hed25583-bib-0002){ref-type="ref"} Although treatments for HNSCC progress rapidly, the 5‐year survival rate is still less than 50%, which represents a therapeutic challenge.[3](#hed25583-bib-0003){ref-type="ref"}, [4](#hed25583-bib-0004){ref-type="ref"} Local recurrence and distant metastasis are main reasons leading to treatment failure. Therefore, it is crucial to identify patients with poor prognosis and strengthen their treatment. The clinical TNM classification system is most frequently used for prognostic evaluation. However, this system only focuses on the anatomic extent of tumor and is insufficient to predict prognosis precisely. Patients with the same TNM classification often have different outcomes. Recently, several new prognostic biomarkers have been explored in HNSCC, such as human papillomavirus (HPV) infection status,[5](#hed25583-bib-0005){ref-type="ref"} cancer stem cell markers,[6](#hed25583-bib-0006){ref-type="ref"} and peripheral blood cell counts and ratios.[7](#hed25583-bib-0007){ref-type="ref"} Accumulated evidence suggests that inflammation plays an essential role in tumorigenesis and tumor progression, which is now included as a hallmark of cancer.[8](#hed25583-bib-0008){ref-type="ref"}, [9](#hed25583-bib-0009){ref-type="ref"} The peripheral inflammatory cells and calculated ratios, especially neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR), have been demonstrated as independent prognostic biomarkers in various cancers, including breast cancer,[10](#hed25583-bib-0010){ref-type="ref"} esophageal carcinoma,[11](#hed25583-bib-0011){ref-type="ref"} colorectal carcinoma,[12](#hed25583-bib-0012){ref-type="ref"} and lung cancer.[13](#hed25583-bib-0013){ref-type="ref"} Opposing to the TNM staging system, which only represents the status of tumor, NLR and PLR could reflect the inflammatory status of host and supplement the TNM staging system. Several studies have assessed the association between level of NLR or PLR and clinical outcomes in HNSCC.[7](#hed25583-bib-0007){ref-type="ref"}, [14](#hed25583-bib-0014){ref-type="ref"}, [15](#hed25583-bib-0015){ref-type="ref"} However, the results remain controversial, because of variation in study design, limited sample size and single‐institution.

A published meta‐analysis, including 100 studies of patients with unselected solid tumors, revealed that elevated NLR was associated with worse overall survival (OS) in all disease sites, subgroups, and stages.[16](#hed25583-bib-0016){ref-type="ref"} However, this meta‐analysis only included two studies on NPC, and no studies on non‐nasopharyngeal HNSCC. As is well known, NPC has distinct genotype, clinical phenotype, and prognosis from HNSCC, which is more sensitive to regular chemotherapy and radiotherapy.[17](#hed25583-bib-0017){ref-type="ref"} Besides this, there have been several meta‐analyses reporting the association between the NLR and the prognosis in NPC.[17](#hed25583-bib-0017){ref-type="ref"}, [18](#hed25583-bib-0018){ref-type="ref"}, [19](#hed25583-bib-0019){ref-type="ref"} Thus, a more comprehensive meta‐analysis to evaluate the prognostic role of NLR and PLR on non‐nasopharyngeal HNSCC is warranted. Moreover, NLR and PLR are cost‐effective and easily available in pretreatment evaluation of the blood test compared with other prognostic factors.

In the present meta‐analysis, we collected and pooled the related literatures to quantify the predictive impact of peripheral blood NLR and PLR on survival prognosis in patients with HNSCC.

2. PATIENTS AND METHODS {#hed25583-sec-0006}
=======================

2.1. Search strategy {#hed25583-sec-0007}
--------------------

The databases of PubMed, Embase, Web of Science and the Cochrane library literature were thoroughly searched up to July 3, 2017. Only English literatures were considered. The searching strategy was randomly combing the following terms: HNSCC ("head and neck squamous cell" or "oral" or "laryn\*" or "pharyn\*" or "tongue" or "oropharyn\*" or "hypopharyn\*"), cancer ("carcinoma" or "tumor" or "neoplasm") and NLR ("neutrophil lymphocyte ratio" or "neutrophil to lymphocyte ratio" or "neutrophil‐to‐lymphocyte ratio") or PLR ("platelet lymphocyte ratio" or "platelet to lymphocyte ratio" or "platelet‐to‐lymphocyte ratio"). All candidate publications and their bibliographies were manually inspected by two reviewers independently for potential relevant articles. Discrepancies were resolved in consensus.

2.2. Eligibility criteria {#hed25583-sec-0008}
-------------------------

The eligibility criteria were listed as follows: (1) the diagnosis of HNSCC was proved based on histological result, and NPC was excluded; (2) articles evaluated the relationship between NLR or PLR and survival prognosis; (3) the hazard ratio (HR) and their 95% confidence interval (CI) were provided or could be calculated from the original article; (4) articles were published as original research in English. To duplicated publications or overlapped data, only the most recent or more comprehensive article was included. The exclusion criteria were: (1) reviews, letters, meeting abstract; (2) nonhuman studies; (3) articles including only NPC; (4) sample size \<50 patients. Two independent reviewers assessed the eligibility of article independently. Any discrepancy was discussed and resolved by consensus.

2.3. Information extraction {#hed25583-sec-0009}
---------------------------

Two reviewers extracted the following information from the included studies independently: first author\'s last name, year of publication, study country, sample size, tumor location, clinicopathological parameters, cutoff value of NLR and PLR, survival data (OS, disease‐free survival \[DFS\], progression‐free survival \[PFS\], cancer specific survival \[CSS\], loco‐regional recurrence‐free survival \[LRRFS\], metastases‐free survival \[MFS\], recurrence‐free survival \[RFS\], and disease‐specific survival \[DSS\]). If univariate and multivariate HRs were both reported, multivariate data were used. Consensus was reached by discussion when inconsistent results exist.

2.4. Extraction of HR {#hed25583-sec-0010}
---------------------

If HRs and their 95% CIs were described in literatures, they were extracted directly. Otherwise, they were calculated from raw data or survival curves by methods of Parmar and Tierney.[20](#hed25583-bib-0020){ref-type="ref"}, [21](#hed25583-bib-0021){ref-type="ref"}

2.5. Quality assessment {#hed25583-sec-0011}
-----------------------

The quality of included literatures was evaluated independently by two reviewers according to the Newcastle‐Ottawa Scale (NOS).[22](#hed25583-bib-0022){ref-type="ref"} Studies with NOS score ≥ 6 were defined as high quality. Disagreements were resolved by discussion.

2.6. Statistical analysis {#hed25583-sec-0012}
-------------------------

A pooled HR \> 1 and 95% CI not overlap 1 (*P* \< .05) represented worse survival prognosis for high NLR or PLR group in HNSCC. The heterogeneity among the included studies was assessed by the Cochran *Q*‐test and *I* ^2^ test. Cochran Q‐test\'s *P* ≤ .10 or *I* ^2^ value ≥50% in *I* ^2^ test indicated significant heterogeneity among studies and random‐effects models were used to calculate the pooled HR and 95% CI. Otherwise, fixed‐effects models were performed. Stratified analyses were carried out to explore the factors potentially influencing the predictive value of NLR or PLR on HNSCC. Sensitivity analysis was applied to verify the stability of the pooled results. To evaluate publication bias, a funnel plot with Begg\'s and Egger\'s test was conducted. And *P* \> .05 was considered as no publication bias. All statistical analyses were performed by STATA Statistical Software, version 12.0 (Stata Corporation, College Station, Texas).

3. RESULTS {#hed25583-sec-0013}
==========

3.1. Characteristics of eligible studies {#hed25583-sec-0014}
----------------------------------------

A flowchart showed the detailed study election procedure (Figure [1](#hed25583-fig-0001){ref-type="fig"}). A total of 118 relevant publications in English were initially identified by our search strategy. Through title and abstract screening, 86 articles were excluded. Subsequently, by full text review, 3 articles were further excluded because the same cohorts of patients were used in other selected literatures, 3 articles were excluded because of insufficient survival data to extract HR, and 1 article was excluded due to sample size \<50. Finally, 25 studies with 28 cohorts fulfilled the criteria and were eligible in this meta‐analysis. [7](#hed25583-bib-0007){ref-type="ref"}, [14](#hed25583-bib-0014){ref-type="ref"}, [15](#hed25583-bib-0015){ref-type="ref"}, [23](#hed25583-bib-0023){ref-type="ref"}, [24](#hed25583-bib-0024){ref-type="ref"}, [25](#hed25583-bib-0025){ref-type="ref"}, [26](#hed25583-bib-0026){ref-type="ref"}, [27](#hed25583-bib-0027){ref-type="ref"}, [28](#hed25583-bib-0028){ref-type="ref"}, [29](#hed25583-bib-0029){ref-type="ref"}, [30](#hed25583-bib-0030){ref-type="ref"}, [31](#hed25583-bib-0031){ref-type="ref"}, [32](#hed25583-bib-0032){ref-type="ref"}, [33](#hed25583-bib-0033){ref-type="ref"}, [34](#hed25583-bib-0034){ref-type="ref"}, [35](#hed25583-bib-0035){ref-type="ref"}, [36](#hed25583-bib-0036){ref-type="ref"}, [37](#hed25583-bib-0037){ref-type="ref"}, [38](#hed25583-bib-0038){ref-type="ref"}, [39](#hed25583-bib-0039){ref-type="ref"}, [40](#hed25583-bib-0040){ref-type="ref"}, [41](#hed25583-bib-0041){ref-type="ref"}, [42](#hed25583-bib-0042){ref-type="ref"}, [43](#hed25583-bib-0043){ref-type="ref"}, [44](#hed25583-bib-0044){ref-type="ref"} All of them are retrospective observation studies.

![Flow chart of studies selection procedure](HED-41-1525-g001){#hed25583-fig-0001}

As shown in Table [1](#hed25583-tbl-0001){ref-type="table"}, the characteristics of the included studies were summarized, which were conducted from 2013 to June 2017. Among them, 8 studies (1872 cases) were performed in non‐Asians and 17 studies (4975 cases) in Asians. All studies recorded the pretreatment NLR or PLR, except for one study, which reported both the pretreatment and the post‐treatment NLR.[37](#hed25583-bib-0037){ref-type="ref"} The data from the post‐treatment NLR were omitted. Cutoff values for high NLR was defined as from 1.62 to 5 (≥ 2 in 19 studies, \< 2 in 4 studies, and unknown in 2 studies), for high PLR was from 81.62 to 300. Seven studies included patients with TNM stage III‐IV, 14 studies included patients with mixed TNM stage (I‐ IV), 1 study included patients with I‐II, and 3 studies did not describe the status of TNM classification.

###### 

Characteristics of studies included in this meta‐analysis

  Author                                              Year   Country     Sample size   Tumorsite   Tumor stage   NLR cutoff      PLR cutoff   Outcome        HR/model   NOS score
  --------------------------------------------------- ------ ----------- ------------- ----------- ------------- --------------- ------------ -------------- ---------- -----------
  Fang[23](#hed25583-bib-0023){ref-type="ref"}        2013   China       226           OC          I‐IV          2.44            \_           OS, DFS        R/U        7
  Tsai[24](#hed25583-bib-0024){ref-type="ref"}        2014   China       202           OC          NA            5               \_           CSS            R/U        8
  Young[25](#hed25583-bib-0025){ref-type="ref"}       2014   UK          251           OP          I‐IV          5               \_           OS             E/U        8
  Moon[26](#hed25583-bib-0026){ref-type="ref"}        2015   Korea       153           HN          I‐IV          NA              \_           OS, PFS, CSS   R/M        8
  Rassouli[7](#hed25583-bib-0007){ref-type="ref"}     2015   Canada      273           HN          NA            4.2             170          DFS            E/U        8
  Salim[27](#hed25583-bib-0027){ref-type="ref"}       2015   Turkey      79            HN          IV            2.93            \_           OS, PFS        E/M        6
  Selzer[14](#hed25583-bib-0014){ref-type="ref"}      2015   Austria     318           HN          I‐IV          5               150‐300      OS             R, E/M     7
  Song[28](#hed25583-bib-0028){ref-type="ref"}        2015   China       146           HP          NA            2.3             \_           OS             E/U        7
  Tu[29](#hed25583-bib-0029){ref-type="ref"}          2015   China       141           L           I‐IV          2.17            \_           OS, DFS        R/M        7
  Charles[30](#hed25583-bib-0030){ref-type="ref"}     2016   Australia   145           HN          I‐IV          5               \_           OS             R/M        7
  Rachidi[31](#hed25583-bib-0031){ref-type="ref"}     2016   America     543           HN          I‐IV          2.36‐4.39       \_           OS             R/M        8
  Zeng[32](#hed25583-bib-0032){ref-type="ref"}        2016   China       125           L           III‐IV        3               \_           OS, PFS        R/M        7
  Nakashima[33](#hed25583-bib-0033){ref-type="ref"}   2016   Japan       124           OC          III‐IV        2.4             \_           DFS            R/M        7
  Ong[34](#hed25583-bib-0034){ref-type="ref"}         2016   China       133           OC          I‐II          NA              129          OS, DFS        R/M        7
  Wong[15](#hed25583-bib-0015){ref-type="ref"}        2016   UK          140           L           I‐IV          1.78‐2.41‐3.1   \_           OS, DFS        R/M        8
  Kano[35](#hed25583-bib-0035){ref-type="ref"}        2016   Japan       285           HN          I‐IV          1.92            125          OS, DFS        R,E/U      8
  Fu[36](#hed25583-bib-0036){ref-type="ref"}          2016   China       420           L           III‐IV        2.59            \_           OS, CSS        R/M        7
  Kim[37](#hed25583-bib-0037){ref-type="ref"}         2016   Korea       104           HN          III‐IV        3               \_           OS, PFS        R/M        7
  Nakahira[38](#hed25583-bib-0038){ref-type="ref"}    2016   Japan       100           HP          I‐IV          3               150          CSS            R/U        7
  Rosculet[39](#hed25583-bib-0039){ref-type="ref"}    2017   America     123           HN          I‐IV          2.7             \_           OS             R/U        8
  Lo[40](#hed25583-bib-0040){ref-type="ref"}          2017   China       105           HP          III‐IV        3.22            \_           OS, DFS        R/M        7
  Ikeguchi[41](#hed25583-bib-0041){ref-type="ref"}    2016   Japan       59            HP          III‐IV        5               \_           OS             R/M        6
  Hsueh[42](#hed25583-bib-0042){ref-type="ref"}       2017   China       979           L           I‐IV          1.62‐2.4        81.62‐111    DFS, CSS       R/M        8
  Bobdey[43](#hed25583-bib-0043){ref-type="ref"}      2017   India       471           OC          I‐IV          2.38            \_           OS             R/U        7
  Chen[44](#hed25583-bib-0044){ref-type="ref"}        2016   China       1202          OC          I‐IV          1.94‐3.66       \_           OS             R/M        7

Abbreviations: CSS, cancer‐specific survival; DFS, disease‐free survival; E: reported in text; E, estimated; HN, head and neck; HP, hypopharynx; HR, hazard ratio; L, larynx; M: multivariate; NA: not available; NOS, Newcastle‐Ottawa Quality Assessment Scale; OC, oral cavity; OP, oropharynx; OS: overall survival; PFS, progression‐free survival; U: univariate.

The numbers of studies reporting the effect of NLR on LRRFS, MFS, RFS, and DSS were no more than two. Thus, only OS, DFS, CSS and PFS were selected as the endpoints of NLR‐related meta‐analysis. No study reported the effect of PLR on PFS, LRRFS, MFS, RFS and DSS, and only 2 studies on CSS. Therefore, for PLR, only OS and DFS were adopted as the endpoints. NOS scores of the included studies ranged from 6 to 9, suggesting high quality.

3.2. Impact of NLR on OS {#hed25583-sec-0015}
------------------------

For all 20 studies (23 cohorts) reporting the effect of NLR on OS, the heterogeneity test suggested a high heterogeneity (*I* ^2^ = 83.3%; *P* \< .001). Consequently, the random‐effect model was used and the combined HR was 1.68 (95% CI, 1.39‐2.03; *P* \< .001), indicating that high NLR was significantly associated with poor OS in HNSCC (Figure [2](#hed25583-fig-0002){ref-type="fig"}).

![Forest plot of hazard ratio (HR) for the impact of NLR on overall survival (OS). NLR, neutrophil‐to‐lymphocyte ratio; CI, confidence interval \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](HED-41-1525-g002){#hed25583-fig-0002}

Subgroup analysis was stratified according to tumor location, ethnicity, sample size, cutoff value of NLR, TNM classification, and statistical model (univariate or multivariate), which correlated with patient\'s prognosis or the NLR, and might bring heterogeneity to the overall analysis. As listed in Table [2](#hed25583-tbl-0002){ref-type="table"}, the prognostic value of high NLR on poor OS was significant in squamous cell carcinoma of oral cavity (HR = 1.59; 95% CI, 1.36‐1.85; *P* \< .001), oropharynx (HR = 2.70; 95% CI, 1.74‐4.18; *P* \< .001), hypopharynx (HR = 2.88; 95% CI, 2.06‐4.03; *P* \< .001) and Larynx (HR = 1.65; 95% CI, 1.24‐2.19; *P* \< .001). Moreover, the heterogeneity in individual subgroups reduced to be mild (oral cavity, *I* ^2^ = 0.0%; *P* = .799; oropharynx, *I* ^2^ = 0.0%; *P* = .494; hypopharynx, *I* ^2^ = 0.0%; *P* = .624; larynx, *I* ^2^ = 43.2%; *P* = .152), which demonstrated that tumor location was a major cause of the high heterogeneity. In term of sample size, ethnicity, TNM classification, and statistical model, subgroup analyses revealed the significant prognostic role of the NLR on OS in all subgroups, suggesting the reliability of our findings. As shown in Table [2](#hed25583-tbl-0002){ref-type="table"}, the stratified analysis by cutoff point of NLR revealed that the significant association between high NLR and poor OS existed in both NLR ≥ 2 subgroup (HR = 1.70; 95% CI = 1.35‐2.14; *P* \< .001) and NLR \< 2 subgroup (HR = 1.50; 95% CI = 1.02‐2.22; *P* = .041). However, the association in NLR \< 2 subgroup tended to be mild.

###### 

Main results of the subgroup analyses for the impact of NLR on OS

  Subgroup analysis    No. of Cohorts   No. of Patients   HR (95% CI)         *P*      Heterogeneity test   
  -------------------- ---------------- ----------------- ------------------- -------- -------------------- --------
  OS                                                                                                        
  Overall              23               5169              1.68 (1.39, 2.03)   \<.001   83.3%                \<.001
  Tumor location                                                                                            
  Oral cavity          5                2032              1.59 (1.36, 1.85)   \<.001   0.0%                 .799
  Oropharynx           3                396               2.70 (1.74, 4.18)   \<.001   0.0%                 .494
  Hypopharynx          3                310               2.88 (2.06, 4.03)   \<.001   0.0%                 .624
  Larynx               4                826               1.65 (1.24, 2.19)   .001     43.2%                .152
  Ethnicity                                                                                                 
  Asian                14               3570              1.69 (1.41, 2.02)   \<.001   57.2%                .004
  Non‐Asian            9                1599              1.65 (1.12, 2.43)   .012     81.4%                \<.001
  Sample size                                                                                               
  ≥200                 10               3716              1.26 (1.02, 1.56)   .032     81.3%                \<.001
  \<200                13               1453              2.17 (1.79, 2.63)   \<.001   20.4%                .238
  Cutoff value                                                                                              
  \<2                  4                1627              1.50 (1.02--2.22)   .041     75.0%                .007
  ≥2                   17               3256              1.70 (1.35--2.14)   \<.001   82.7%                \<.001
  TNM classification                                                                                        
  III‐IV               6                892               1.64 (1.29‐2.09)    \<.001   34.4%                .178
  Mix(I‐IV)            15               3998              1.58 (1.25‐2.01)    \<.001   83.1%                \<.001
  Uni/multivariate                                                                                          
  Univariate           6                1502              1.79 (1.16‐2.76)    .008     77.3%                .001
  Multivariate         17               3667              1.63 (1.32‐2.03)    \<.001   82.0%                \<.001

Abbreviations: CI, confidence interval; NLR, neutrophil‐to‐lymphocyte ratio; No, number; OS, overall survival.

3.3. Impact of NLR on DFS {#hed25583-sec-0016}
-------------------------

Among the 9 studies reporting the role of NLR on DFS, results indicated that high NLR could predict poor DFS (HR = 1.76; 95% CI, 1.42‐2.17; *P* \< .001) using the random‐effect model, as high heterogeneity was detected (*I* ^2^ = 44.6%; *P* = .071) (Figure [3](#hed25583-fig-0003){ref-type="fig"}A).

![Forest plot of HR for the impact of NLR on A, DFS; B, PFS; C, CSS. HR, hazard ratio; CI, confidence interval; CSS, cancer‐specific survival; DFS, disease‐free survival; NLR, neutrophil‐to‐lymphocyte ratio; PFS, progression‐free survival \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](HED-41-1525-g003){#hed25583-fig-0003}

Stratified analysis was conducted by tumor location, ethnicity, sample size, cutoff value of NLR, TNM classification, and statistical model. Results also suggested significant prognostic effect of high NLR on poor DFS in squamous cell carcinoma of oral cavity (HR = 1.69; 95% CI, 1.24‐2.30; *P* = .001) and larynx (HR = 1.36; 95% CI, 1.13‐1.63; *P* = .001) (Table [3](#hed25583-tbl-0003){ref-type="table"}). Due to limited studies, the subgroup analyses in squamous cell carcinoma of hypopharynx and oropharynx could not be carried out. Similarly, the heterogeneity decreased to be acceptable in oral cavity (*I* ^2^ = 0.0%; *P* = .817) and larynx (*I* ^2^ = 0.0%; *P* = .404) subgroups. As shown in Table [3](#hed25583-tbl-0003){ref-type="table"}, stratified analyses based on sample size, cutoff value of NLR, tumor TNM classification, and statistical model showed that these factors had no significant effect on the association between high NLR and poor DFS. However, the subgroup analysis by ethnicity revealed that high NLR could predict poor DFS in Asians (HR = 1.64; 95% CI, 1.35‐1.98; *P* \< .001), but not in non‐Asians (HR = 2.55; 95% CI, 0.78‐8.36; *P* = .122) (Table [3](#hed25583-tbl-0003){ref-type="table"}). Given only two studies included non‐Asian patients, this conclusion need to be verified further.

###### 

Main results of the subgroup analyses for the impact of NLR on DFS

  Subgroup analysis    No. of cohorts   No. of patients   HR (95%CI)          *P*      Heterogeneity test   
  -------------------- ---------------- ----------------- ------------------- -------- -------------------- ------
  DFS                                                                                                       
  Overall              9                2406              1.76 (1.42, 2.17)   \<.001   44.6%                .071
  Tumor location                                                                                            
  Oropharynx           3                483               1.69 (1.24, 2.30)   .001     0.0%                 .817
  Larynx               3                1260              1.36 (1.13, 1.63)   .001     0.0%                 .404
  Ethnicity                                                                                                 
  Asian                7                1993              1.64 (1.35, 1.98)   \<.001   22.9%                .254
  Non‐Asian            2                413               2.55 (0.78, 8.36)   .122     82.9%                .016
  Sample size                                                                                               
  ≥200                 4                1763              1.93 (1.23, 3.03)   .004     75.1%                .007
  \<200                5                643               1.72 (1.36, 2.18)   \<.001   0.0%                 .800
  Cutoff value                                                                                              
  \<2                  2                425               1.77 (1.24‐2.51)    .002     60.1%                .028
  ≥2                   6                1848              1.89 (1.36‐2.63)    \<.001   23.4%                .253
  TNM classification                                                                                        
  III‐IV               2                229               2.11 (1.36‐3.27)    .001     0.0%                 .862
  Mix(I‐IV)            5                1771              1.55 (1.26‐1.91)    \<.001   27.7%                .237
  Uni/multivariate                                                                                          
  Univariate           3                784               2.33 (1.44‐3.78)    .001     52.7%                .121
  Multivariate         6                1622              1.47 (1.25‐1.74)    \<.001   3.5%                 .394

Abbreviations: CI, confidence interval; DFS, disease free‐survival; HR, hazard ratio; No, number; NLR, neutrophil‐to‐lymphocyte ratio.

3.4. Impact of NLR on PFS {#hed25583-sec-0017}
-------------------------

There were 4 studies reporting the impact of NLR on PFS. Since high heterogeneity (*I* ^2^ = 60.0%; *P* = .058) was evaluated, meta‐analysis using the random‐effect model showed significant association between high NLR and poor PFS (HR = 1.53; 95% CI, 1.09‐2.14; *P* = .014) (Figure [3](#hed25583-fig-0003){ref-type="fig"}B). Due to insufficient studies, subgroup analysis could not be performed.

3.5. Impact of NLR on CSS {#hed25583-sec-0018}
-------------------------

Five studies with mild heterogeneity (*I* ^2^ = 35.9%; *P* = .182), which reported the predictive effect of the NLR on CSS, were combined by the fixed‐effect model. And results indicated that high NLR was significantly correlated with worse CSS in HNSCC (HR = 1.45; 95% CI, 1.23‐1.71; *P* \< .001) (Figure [3](#hed25583-fig-0003){ref-type="fig"}C). Given limited studies, no subgroup analysis was conducted.

3.6. Impact of PLR on OS and DFS {#hed25583-sec-0019}
--------------------------------

Regarding PLR, 4 literatures reported the predictive effect of PLR on OS and 3 literatures on DFS. The random‐effects models were used because of significant heterogeneity (OS: *I* ^2^ = 75.9%; *P* = .006; DFS: *I* ^2^ = 84.5%; *P* = .002). And results indicated no significant association between PLR and OS (HR = 0.94; 95% CI, 0.65‐1.36; *P* = .743) or DFS (HR = 1.26; 95% CI, 0.94‐1.68; *P* = .119) in HNSCC. (Figure [4](#hed25583-fig-0004){ref-type="fig"}A,B).

![Forest plot of HR for the impact of PLR on A, OS; B, DFS. CI, confidence interval; DFS, disease‐free survival; HR, hazard ratio; OS, overall survival; PLR, platelet‐to‐lymphocyte ratio \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](HED-41-1525-g004){#hed25583-fig-0004}

3.7. Publication bias and sensitivity analysis {#hed25583-sec-0020}
----------------------------------------------

The publication bias was assessed using Begg\'s funnel plot and Egger\'s test. Among the 20 studies reporting the effect of NLR on OS, Begg\'s test found acceptable publication bias (*P =* .291), whereas Egger\'s test detected a publication bias (*P =* .044). In terms of the 9 studies reporting the impact of NLR on DFS, both Begg\'s test (*P =* .048) and Egg\'s test (*P \<* .001) revealed significant publication bias. The shapes of the Begg\'s funnel plot also seemed not so symmetrical by visual inspection (Figure [5](#hed25583-fig-0005){ref-type="fig"}A,B). Since limited studies were included in other analyses, the evaluation of publication bias was not conducted.

![Funnel plot for included studies in the meta‐analysis. A, Studies for the impact of NLR on OS. B, Studies for the impact of NLR on DFS. DFS, disease‐free survival; NLR, neutrophil‐to‐lymphocyte ratio; OS, overall survival \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](HED-41-1525-g005){#hed25583-fig-0005}

Subsequently, sensitivity analyses were performed to evaluate the reliability of the meta‐analysis results by sequentially removing individual study from pooled analysis. Results demonstrated that omission of single study did not statistically change the results of the impact of NLR on OS (Table [4](#hed25583-tbl-0004){ref-type="table"}) and DFS (Table [5](#hed25583-tbl-0005){ref-type="table"}), which suggested the stability of our results.

###### 

Sensitivity analysis of HR for the impact of NLR on OS

  Study omitted                                       HR (95% CI)         *P*       *I* ^2^   *P* ~*H*~
  --------------------------------------------------- ------------------- --------- --------- -----------
  Moon[26](#hed25583-bib-0026){ref-type="ref"}        1.64 (1.35, 1.99)   \<.001    83.1%     \<.001
  Salim[27](#hed25583-bib-0027){ref-type="ref"}       1.67 (1.37, 2.03)   \<.001    83.6%     \<.001
  Kim[37](#hed25583-bib-0037){ref-type="ref"}         1.69 (1.38, 2.06)   \<.001    83.8%     \<.001
  Rosculet[39](#hed25583-bib-0039){ref-type="ref"}    1.65 (1.36, 2.00)   \<0.001   83.4%     \<.001
  Song[28](#hed25583-bib-0028){ref-type="ref"}        1.61 (1.34, 1.95)   \<.001    81.1%     \<.001
  Lo[40](#hed25583-bib-0040){ref-type="ref"}          1.64(1.35, 1.99)    \<.001    82.7%     \<.001
  Ikeguchi[41](#hed25583-bib-0041){ref-type="ref"}    1.65 (1.36, 2.00)   \<.001    83.5%     \<.001
  Tu[29](#hed25583-bib-0029){ref-type="ref"}          1.66(1.36, 2.01)    \<.001    83.3%     \<.001
  Zeng[32](#hed25583-bib-0032){ref-type="ref"}        1.69(1.39, 2.07)    \<.001    83.6%     \<.001
  Wong[15](#hed25583-bib-0015){ref-type="ref"}        1.65 (1.36, 2.00)   \<.001    83.0%     \<.001
  Charles 1[30](#hed25583-bib-0030){ref-type="ref"}   1.65 (1.36, 1.99)   \<.001    83.4%     \<.001
  Charles 2[30](#hed25583-bib-0030){ref-type="ref"}   1.64 (1.36, 1.99)   \<.001    83.3%     \<.001
  Ong[34](#hed25583-bib-0034){ref-type="ref"}         1.68 (1.38, 2.05)   \<.001    83.7%     \<.001
  Selzer 1[14](#hed25583-bib-0014){ref-type="ref"}    1.77 (1.46, 2.15)   \<.001    83.1%     \<.001
  Selzer 2[14](#hed25583-bib-0014){ref-type="ref"}    1.71 (1.41, 2.09)   \<.001    84.0%     \<.001
  Rachidi[31](#hed25583-bib-0031){ref-type="ref"}     1.72 (1.43, 2.07)   \<.001    66.4%     \<.001
  Kano[35](#hed25583-bib-0035){ref-type="ref"}        1.75 (1.44, 2.13)   \<.001    83.8%     \<.001
  Fu[36](#hed25583-bib-0036){ref-type="ref"}          1.71 (1.40, 2.11)   \<.001    83.7%     \<.001
  Young[25](#hed25583-bib-0025){ref-type="ref"}       1.65 (1.36, 2.00)   \<.001    83.0%     \<.001
  Fang[23](#hed25583-bib-0023){ref-type="ref"}        1.66 (1.37, 2.02)   \<.001    83.6%     \<.001
  Bobdey[43](#hed25583-bib-0043){ref-type="ref"}      1.71 (1.39, 2.09)   \<.001    83.6%     \<.001
  Chen 1[44](#hed25583-bib-0044){ref-type="ref"}      1.69 (1.38, 2.07)   \<.001    82.6%     \<.001
  Chen 2[44](#hed25583-bib-0044){ref-type="ref"}      1.67 (1.37, 2.04)   \<.001    83.0%     \<.001

Abbreviations: CI, confidence interval; HR, hazard ratio; NLR, neutrophil‐to‐lymphocyte ratio; OS, overall survival; *P* ~*H*~ *,* the *P* value of Cochran *Q*‐test for heterogeneity.

###### 

Sensitivity analysis of HR for the impact of NLR on DFS

  Study omitted                                       HR (95% CI)         *p*      *I* ^2^   *P* ~*H:*~
  --------------------------------------------------- ------------------- -------- --------- ------------
  Lo[40](#hed25583-bib-0040){ref-type="ref"}          1.72 (1.37, 2.16)   \<.001   46.7%     .069
  Wong[15](#hed25583-bib-0015){ref-type="ref"}        1.83 (1.43, 2.34)   \<.001   51.1%     .046
  Tu[29](#hed25583-bib-0029){ref-type="ref"}          1.76 (1.39, 2.23)   \<.001   50.2%     .050
  Ong[34](#hed25583-bib-0034){ref-type="ref"}         1.81 (1.42, 2.31)   \<.001   51.4%     .044
  Nakashima[33](#hed25583-bib-0033){ref-type="ref"}   1.75 (1.39, 2.20)   \<.001   49.9%     .052
  Hsueh[42](#hed25583-bib-0042){ref-type="ref"}       1.88 (1.55, 2.27)   \<.001   3.6%      .402
  Fang[23](#hed25583-bib-0023){ref-type="ref"}        1.78 (1.40, 2.27)   \<.001   51.1%     .046
  Kano[35](#hed25583-bib-0035){ref-type="ref"}        1.71 (1.36, 2.15)   \<.001   44.3%     .083
  Rassouli[7](#hed25583-bib-0007){ref-type="ref"}     1.58 (1.35, 1.85)   \<.001   10.5%     .349

Abbreviations: NLR, Neutrophil‐to‐lymphocyte ratio; DFS, disease free survival; HR, hazard ratio; CI, confidence interval; *P* ~*H,*~ the P value of Cochran *Q*‐test for heterogeneity.

4. DISCUSSION {#hed25583-sec-0021}
=============

To the best of our knowledge, this is the most comprehensive meta‐analysis investigating the prognostic value of NLR and PLR in HNSCC. Our results from 25 literatures with 28 cohorts involving 6847 HNSCC patients confirmed that high level of pretreatment NLR was significantly associated with poor OS, DFS, PFS, and CSS. By contrast, PLR was evaluated to have no significant predictive role on either OS or DFS in HNSCC.

Recently, a meta‐analysis published by Takenaka et al. investigated the prognostic role of NLR in HNSCC.[45](#hed25583-bib-0045){ref-type="ref"} However, in the present meta‐analysis, we included more studies (25 vs 19 studies in Takenaka\'s) and greater number of HNSCC patients (6847 vs 3770 patients in Takenaka\'s). Moreover, we conducted more comprehensive analysis on the association between both the NLR and PLR, and OS, DFS, PFS, and CSS. Takenaka et al. only focused on the relationship between NLR and OS, or DSS. Importantly, the similar results of the two meta‐analyses further support the potential prognostic role of NLR in HNSCC.

It remains poorly understood for the mechanisms underlying the association between NLR or PLR and oncologic prognosis. For neutrophil, first, it has been verified to promote angiogenesis, cell growth, tumorigenesis, and tumor progression by secreting vascular endothelial growth factor, hepatocyte growth factor, IL‐6, IL‐8, and matrix metalloproteinases.[46](#hed25583-bib-0046){ref-type="ref"}, [47](#hed25583-bib-0047){ref-type="ref"}, [48](#hed25583-bib-0048){ref-type="ref"}, [49](#hed25583-bib-0049){ref-type="ref"}, [50](#hed25583-bib-0050){ref-type="ref"} Second, neutrophil has been demonstrated to suppress the cytotoxic activity of lymphocytes, natural killer cells, and activated T cells through producing reactive oxygen species, arginase, and nitric oxide.[51](#hed25583-bib-0051){ref-type="ref"}, [52](#hed25583-bib-0052){ref-type="ref"} Therefore, elevated neutrophil counts are frequently associated with poor prognosis in cancer. Whereas, for lymphocyte, it is essential to activate effective antitumor response in host immune system.[53](#hed25583-bib-0053){ref-type="ref"} Decreased lymphocyte counts often indicate suppression of lymphocyte‐mediated antitumor immunity and poor clinical outcome. NLR has been widely assumed as a marker of upregulated host inflammation to promote the progression of tumor.[54](#hed25583-bib-0054){ref-type="ref"} Meanwhile, platelet is considered to promote tumor cell growth and metastases via contacting cancer cells directly and secreting bioactive proteins relevant to tumor angiogenesis and osteoclast resorption.[55](#hed25583-bib-0055){ref-type="ref"} PLR also has emerged as an independent prognostic factor in various cancers.[7](#hed25583-bib-0007){ref-type="ref"}, [56](#hed25583-bib-0056){ref-type="ref"}, [57](#hed25583-bib-0057){ref-type="ref"}

Notably, HNSCC is a heterogeneous disease, including squamous cell carcinoma from oral cavity, oropharynx, larynx, and hypopharynx. Tumor location is an important factor, which influences the survival prognosis of HNSCC. In subgroup analyses based on tumor location, NLR showed significant association with OS and DFS in all subpopulations. Moreover, the heterogeneity among studies in individual subgroups reduced to be acceptable, suggesting that tumor location is the main cause of high heterogeneity in the overall meta‐analysis. In addition, it represents the robustness and stability of our results about the impact of NLR on OS and DFS. Subgroup analyses stratified by ethnicity and sample size also suggested the similar results in all subgroups, except for DFS in non‐Asians. Due to only two studies including non‐Asian patients, future large‐scale prospective trials are required before a definite conclusion can be made.

Treatment strategy and clinical stage also have been manifested to be crucial prognostic factors in HNSCC. Nowadays, comprehensive treatment is standard in HNSCC, which is utilized in majority of the included studies. Therefore, the issue whether individual treatment strategy influences the correlation between NLR or PLR and survival prognosis could not be investigated in our study. In terms of tumor stage, due to the limited information in the included literatures, we could not separate the patients precisely. Consequently, only TNM stage III‐IV subgroup and mixed stage (I‐IV) subgroup were divided. And the results of stratified analysis revealed that the high NLR predicted poor OS and DFS in both subgroups (Tables [2](#hed25583-tbl-0002){ref-type="table"} and [3](#hed25583-tbl-0003){ref-type="table"}), which is warranted be explored further in the future studies.

Another well‐documented prognostic factor for HNSCC is HPV status.[5](#hed25583-bib-0005){ref-type="ref"} What is more, HPV infection could modulate the host immune response to the tumor and influence the NLR.[39](#hed25583-bib-0039){ref-type="ref"} Consequently, the impact of HPV status on the predictive role of NLR or PLR should be taken into account. However, only two included studies reported the HPV status and concluded conversely.[31](#hed25583-bib-0031){ref-type="ref"}, [39](#hed25583-bib-0039){ref-type="ref"} Rachidi et al. revealed that the NLR predicted survival regardless of HPV status.[31](#hed25583-bib-0031){ref-type="ref"} Whereas, Rosculet et al. suggested that the NLR does not have independent prognostic significance in the favorable prognostic HNSCC patients with HPV‐positive tumor. The conflict findings call for more in‐depth investigation. Given limited studies, the impact of HPV status on the relationship between NLR and survival prognosis in HNSCC were not further explored here.

As well known, the NLR and PLR are nonspecific parameters, which could be influenced by many other conditions, such as age, infection, hypertension, inflammatory diseases, and medications.[58](#hed25583-bib-0058){ref-type="ref"}, [59](#hed25583-bib-0059){ref-type="ref"} Its nonspecificity for using it as a prognostic marker comes into doubt. However, another nonspecific parameter lactate dehydrogenase, which also could be affected by infection, liver injury, and cancer,[60](#hed25583-bib-0060){ref-type="ref"}, [61](#hed25583-bib-0061){ref-type="ref"} is an important item in the widely assumed international prognostic index for Non‐Hodgkin\'s lymphoma. Actually, Templeton et al. have already cooperated the NLR in a simple score in metastatic castration‐resistant prostate cancer to help predict prognosis and tailor therapy.[62](#hed25583-bib-0062){ref-type="ref"} All these suggest that it is available and reasonable to add NLR in establishing prognostic system for cancer.

As a literature‐based meta‐analysis, some limitations of our study should be noticed. First, all of the included studies were retrospective and observational. Potential selection bias may exist. Therefore, prospective randomized controlled studies are warranted to confirm our findings. Second, there was evidence of publication bias, potentially indicating bias towards publication of positive studies. And language limitations in the inclusion criterion might also account for the bias. However, sensitivity analysis verified the reliability of our findings. Third, in several studies, the HRs and CIs had to be calculated from survival curves, given no parameters reported directly, which might bring in small errors. But the stable results of our sensitivity analyses suggested that the effects of such errors were limited. Fourth, most of the included studies (17 studies out of 25 studies) with 4975 cases (out of 6847 patients) were performed in Asians, the results about non‐Asians should be concluded carefully and need to be verified further. At last, there are no standard cutoff values for NLR and PLR among the included studies, with NLR ranged from 1.62 to 5 and PLR from 81.62 to 300. However, Templeton et al. considered that the range of NLR cutoffs was considered narrow and unlikely to influence the association between NLR and reported HR for survival,^16^ which was in consistent with our results. Since the association between the NLR and OS prognosis decreased to be mild in cutoff value of NLR \< 2 subgroup (HR = 1.50; 95% CI = 1.02‐2.22; *P* = .041), we suggested that the cutoff value of NLR should be set up more than 2 in future studies.

In summary, our results suggest that the elevated NLR is significantly associated with adverse OS, DFS, PFS, and CSS in HNSCC, which can serve as a cost‐effective prognostic biomarker to help stratify patients and individualize the treatments. Notably, tumor site is demonstrated to be a major cause leading to the obvious heterogeneity among the included studies. However, our results failed to identify PLR as a predictive factor on either OS or DFS in HNSCC. In the future, multicenter prospective and randomized clinical trials are warranted to confirm such findings and promote the utilization in clinic, especially in cooperation with other prognostic markers.
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